Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.25.3
Segment Information
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information

9. Segment Information

 

The Company operates and manages its business as one reportable and operating segment dedicated to the research and development Company’s novel orally administered antiviral influenza candidate. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis.

 

The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on net income (loss).

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM (table in thousands):

 

    2025     2024  
    Nine months ended September 30,  
    2025     2024  
Research and development     2,737       9,040  
Salaries and personnel costs     1,171       2,403  
Insurance     185       224  
Stock-based compensation     214       557  
Operating expenses     2,231       2,424  
Other income     (133 )     (410 )
Net loss   $ 6,405     $ 14,238